Novo Nordisk A/s

This study is creating a French registry to collect information on children with Noonan Syndrome who are being treated with Norditropin®, a growth hormone. It aims to track their long-term growth, monitor safety, and understand how treatment affects their quality of life. The stu…

This study is testing a new medicine called concizumab to see if it can safely prevent bleeding episodes in people with haemophilia A or B who have developed inhibitors. Participants will give themselves a daily injection under the skin at home for up to seven years. The goal is …

This study is testing a new medicine called concizumab to see if it can safely prevent bleeding episodes in children under 12 who have hemophilia A or B. Participants will give themselves a daily injection under the skin for 2 to 4 years. The main goal is to see if this daily tre…

This study is testing a new, once-a-week growth hormone injection called somapacitan in children who are shorter than average. It includes kids born small, or with Turner syndrome, Noonan syndrome, or unexplained short stature. The main goals are to see if the treatment is safe a…

This study is testing the long-term safety and effectiveness of a new medicine called Mim8 for people with hemophilia A, a condition where blood doesn't clot properly. Mim8 is given as an injection and works by helping the blood to clot, with the goal of preventing bleeding episo…

This 5-year study is testing whether adding a weekly injection called semaglutide to standard diabetes care can slow the progression of diabetic eye disease. About 1,500 adults with type 2 diabetes will receive either semaglutide or a placebo injection. Researchers will track cha…

This study compares a new weekly growth hormone injection (somapacitan) against the standard daily injection (Norditropin®) for children who were born small and remained short. Over 62 children will receive either treatment for 5 years to see if the weekly option works as well an…

This large study is testing whether a weekly injection called CagriSema can reduce serious heart problems like heart attacks and strokes in people who already have heart disease. About 7,100 participants aged 55+ with a history of heart issues will receive either the real injecti…

This study is testing whether a weekly injection called semaglutide can help adolescents with obesity maintain weight loss over the long term. All 500 participants, aged 12 to under 15, will receive the injection for at least three years. The goal is to see if the treatment helps…

This study is testing a new weekly injection called CagriSema, which combines two medicines, to see if it helps people with obesity or overweight lose weight. About 3,400 participants will receive either CagriSema, one of its components alone, or a placebo injection for about a y…

This study is testing whether a daily injection called liraglutide, combined with lifestyle counseling, can help children aged 6 to 12 with obesity manage their weight. For 56 weeks, about 78 children will receive either the real medicine or a placebo (dummy) injection, and neith…

This early-stage study is testing a new injectable medicine for people with overweight or obesity. The main goal is to check if the medicine is safe and to see how the body absorbs and processes it. About 63 healthy adults will receive either the real medicine or a placebo inject…

This study is testing whether a new weekly injection called CagriSema works better than an existing drug called tirzepatide for controlling blood sugar and reducing weight in people with type 2 diabetes. About 1,000 adults whose diabetes isn't well-controlled on metformin will be…

This study is observing 555 adults with obesity in Germany who are already prescribed the medication semaglutide (Wegovy) by their doctor. The goal is to collect real-world data over 12 months on how well the drug, combined with lifestyle changes, helps people lose weight and imp…

This study aims to monitor the safety and effectiveness of the weight-loss medication Wegovy in everyday medical practice in Japan. Over 1000 adults with obesity, who have already been prescribed Wegovy by their doctor, will be followed for two years. Researchers will track side …

This large, late-stage study is testing whether a new monthly injection called ziltivekimab can reduce the risk of major heart problems like heart attacks and strokes. It involves about 6,200 people who already have heart disease, chronic kidney disease, and signs of body-wide in…

This large, late-stage trial is investigating whether a pill called semaglutide, already used for diabetes, can slow the progression of early Alzheimer's disease. About 1,840 participants with mild memory problems will be randomly assigned to receive either the real medication or…

This study will monitor the long-term safety and effectiveness of a preventative treatment (Refixia/REBINYN) for males with hemophilia B. Over 4-9 years, researchers will track side effects, bleeding episodes, and how well the drug controls bleeding during surgery or injuries. Pa…

This early-stage study is testing a new injectable medicine called NNC0519-0130 for people with type 2 diabetes and excess weight. It will measure how the drug moves through the body and check for side effects in 20 Chinese men with overweight or obesity. Participants will receiv…

This study is testing a new weekly injection called CagriSema to see if it helps people with obesity lose weight and keep it off long-term. About 400 adults will receive either the real medicine or a placebo (dummy medicine) for two years, followed by a one-year extension phase. …

This study is testing whether a new investigational medicine called cagrilintide helps people with overweight or obesity lose weight and improve their health. About 300 adults will receive either cagrilintide or a placebo (dummy treatment) by random chance for about 18 months. Re…

This study aims to understand how the weight-loss medication Wegovy works for people with obesity in real-world settings over two years. It will follow about 1,250 adults who are starting Wegovy as part of their regular doctor's care. Researchers will track changes in weight, hea…

This study is testing a new weekly injection called CagriSema to see how well it helps people with obesity lose weight. About 300 adults will receive either the real injection or a placebo (dummy medicine) for about a year and a half. The main goal is to measure how much body wei…

This study compares a new weekly growth hormone injection called somapacitan against the standard daily injection (Norditropin®) in children with short stature. It includes children born small who stayed small, and those with Turner syndrome, Noonan syndrome, or unexplained short…

This study aims to understand if closely following a prescribed growth hormone treatment plan leads to a better final height for children. It will follow up to 750 children and teenagers in Germany with growth hormone deficiency or who were born small for up to 10 years. The main…

This study is testing whether a new weekly injection called CagriSema works better than an existing drug called tirzepatide for controlling type 2 diabetes. About 1,023 adults whose diabetes isn't well-controlled on common pills will be randomly assigned to receive one of these t…

This study is testing whether an investigational medicine called cagrilintide helps people with type 2 diabetes and overweight or obesity lose weight and improve their health. About 330 participants will be randomly assigned to receive either the new medicine or a placebo for abo…

This study is testing a weekly injection called CagriSema to see how well it helps people with obesity lose weight and keep it off for the long term. About 600 participants will receive either the active medicine or a placebo (dummy injection) for over 3 years. Researchers will m…

This study follows males with moderate to severe hemophilia A who are already using Esperoct® to prevent bleeding episodes. Researchers will track how well the treatment works and monitor any side effects over 5-7 years of regular use. Participants continue their normal treatment…

This large, late-stage study is testing if a weekly injection of semaglutide—a medicine already used for type 2 diabetes—can treat non-alcoholic steatohepatitis (NASH), a serious liver condition. About 1,200 adults with NASH and significant liver scarring will receive either the …

This study continues testing an experimental medicine called NNC6019-0001 for people with a serious heart condition caused by protein buildup. It will follow 80 participants for up to 3 years to see how safe the medicine is long-term and whether it helps improve heart function an…

This study is testing whether a new medicine called concizumab can safely prevent bleeding episodes in people with haemophilia A or B who do not have inhibitors. Participants will give themselves a daily injection at home and track their bleeds. The goal is to see if this daily t…

This large, late-stage trial is testing whether a pill called semaglutide, already used for diabetes, can slow the progression of early Alzheimer's disease. About 1,840 participants with mild memory problems will take either the real medicine or a placebo pill for over three year…

This small, early-stage study is testing whether a drug called etavopivat can improve blood flow and oxygen delivery to the brain in children and young adults with sickle cell disease. Researchers will use special light-based scanners to measure brain blood flow in about 12 parti…

This study is testing whether a weekly injection called semaglutide, combined with counseling on healthy eating and activity, can help children and teenagers (ages 6-17) manage their weight over a long period. About 210 participants will be randomly assigned to receive either the…

This study is observing how well the weekly weight-loss injection Wegovy works for Korean adults with obesity in everyday medical practice. About 500 participants will receive the treatment as prescribed by their doctor, and researchers will track their weight, body composition, …

This large international project aims to test community-based programs designed to prevent childhood obesity. It will involve 36,000 children aged 6-13 in disadvantaged areas of six countries. The programs will promote healthy eating and physical activity, and researchers will me…

This study is testing whether weekly injections of an investigational drug called CagriSema can reduce pain from diabetic nerve damage. It will compare CagriSema to a placebo in 142 adults with type 2 diabetes who have had this specific nerve pain for at least 3 months. The main …

This study is collecting feedback from people already using the DuraTouch insulin injection device in their daily lives. About 125 people with type 1 or type 2 diabetes will rate how easy, convenient, and satisfying the device is to use over 12 weeks. The goal is to understand th…

This study aims to better understand how haemophilia affects people and how it is managed in Asia-Pacific countries. It is a survey-based study, so no medications or treatments are provided to participants. Researchers will collect information from patients, caregivers, doctors, …

This study looks at existing health records to understand if taking the weight-loss medication Wegovy during pregnancy affects the health of mothers and babies. Researchers will compare about 1,100 pregnancies where women took Wegovy to pregnancies where they didn't. The goal is …

This is a survey study to learn about the real-world experiences of people using the injectable weight loss medication semaglutide. It will collect online responses from over 2,500 participants in four countries over 14 months. The goal is to understand their satisfaction, weight…

This study is collecting information about pregnancy outcomes for women who take Wegovy (semaglutide) for weight management. Researchers will compare about 728 pregnant women who take Wegovy with similar women who don't take the medication. They'll track birth outcomes, complicat…

This study is collecting safety information from an existing European patient registry. It aims to monitor for any side effects in people with Hemophilia A who are being treated with the medication turoctocog alfa pegol. The study does not involve any new treatment or procedures …

This study aims to observe how people with moderate Parkinson's disease fare over time while on their usual medications. It will follow 96 participants for up to 2 years, tracking their movement symptoms during 'off' periods when medication wears off. A key goal is to see if part…

This study aims to monitor the long-term safety and effectiveness of Sogroya (somapacitan) in adults with growth hormone deficiency who are already receiving it as part of their normal medical care. Over 5 to 10 years, researchers will collect information on side effects, health …

This study aims to learn about health data collection by observing 200 adults with overweight or obesity who are starting a weight management program. Participants will use their own smartphone, along with a provided smartwatch and scale, to share health information remotely for …